- Conditions
- Hyperlipidemia, NAFLD
- Interventions
- VK2809, Placebo
- Drug
- Lead sponsor
- Viking Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 19
- States / cities
- Chandler, Arizona • Garden Grove, California • Los Angeles, California + 13 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 575
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Liver Diseases, Liver Fat, Hepatic Steatosis, Nutritional and Metabolic Disease
- Interventions
- Whole Dairy
- Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Non Alcoholic Steatohepatitis (NASH)
- Interventions
- AXA1125, Placebo
- Drug
- Lead sponsor
- Axcella Health, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 57
- States / cities
- Cullman, Alabama • Tucson, Arizona • Canoga Park, California + 45 more
- Conditions
- Nonalcoholic Fatty Liver Disease
- Interventions
- CB4211 Dose 1, CB4211 Dose 2, CB4211 Dose 3, CB4211 Dose 4, CB4211 Dose 5, CB4211 Dose 6, CB4211 Dose TBD, Placebo
- Drug
- Lead sponsor
- CohBar, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 4
- States / cities
- Chula Vista, California • Dallas, Texas • San Antonio, Texas
- Conditions
- Type II Diabetes, Nonalcoholic Fatty Liver
- Interventions
- DPP4 inhibitor, Pioglitazone, Lantus insulin
- Drug
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Non-alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver
- Interventions
- BT-NCBT-00X
- Device
- Lead sponsor
- Better Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- Chandler, Arizona • Peoria, Arizona
- Conditions
- Food Insecurity
- Interventions
- Food Security Screening & Referral Program
- Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- La Jolla, California • San Diego, California
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver
- Interventions
- Not listed
- Lead sponsor
- University of Oxford
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- NGM282, Placebo
- Biological · Other
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 36
- States / cities
- Chandler, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 28 more
- Conditions
- NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Interventions
- Efruxifermin, Placebo
- Drug
- Lead sponsor
- Akero Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2,150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 171
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 143 more
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Interventions
- Healthy Liver/Hígado Sano program, Usual standard of care
- Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- PXL065, Placebo oral tablet
- Drug
- Lead sponsor
- Poxel SA
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 29
- States / cities
- Chandler, Arizona • Glendale, Arizona • Tucson, Arizona + 24 more
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- TERN-501, TERN-101, Placebo
- Drug · Other
- Lead sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 35
- States / cities
- Chandler, Arizona • Tucson, Arizona • Coronado, California + 26 more
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- GS-9674, Placebo to match GS-9674
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Rialto, California • Coral Gables, Florida + 19 more
- Conditions
- Non-Alcoholic Fatty Liver Disease
- Interventions
- Lovaza, placebo control
- Drug
- Lead sponsor
- Huntington Medical Research Institutes
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- NAFLD
- Interventions
- homocysteine (Hcy) lowering supplements
- Dietary Supplement
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver
- Interventions
- Ultrasound based shear wave speed and fat quantification methods, Blood collection, Physical measurements, Clinical history and medication reviews
- Device · Diagnostic Test · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- San Diego, California • Boston, Massachusetts
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Erchonia Verju Laser, Erchonia EVRL Laser
- Device
- Lead sponsor
- Erchonia Corporation
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Non-Alcoholic Steatohepatitis (NASH)
- Interventions
- Pemvidutide, Placebo
- Drug
- Lead sponsor
- Altimmune, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 29
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 23 more
- Conditions
- Diabetes Complications, Fatty Liver
- Interventions
- exenatide
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Insulin Resistance, Prediabetic State, Hyperinsulinemia, Non-Alcoholic Fatty Liver Disease, Obesity
- Interventions
- Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, CORE Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
- Drug · Other · Dietary Supplement + 1 more
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Nonalcoholic Fatty Liver Disease (NAFLD)
- Interventions
- IMM-124E, Placebo
- Biological · Other
- Lead sponsor
- Miriam Vos, MD
- Other
- Eligibility
- 6 Years to 19 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Non-alcoholic Steatohepatitis, Hepatic Impairment, Cirrhosis
- Interventions
- TVB-2640 - 50 mg
- Drug
- Lead sponsor
- Sagimet Biosciences Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 2
- States / cities
- Orlando, Florida • San Antonio, Texas
- Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Interventions
- Placebo, leronlimab 700 mg, leronlimab 350 mg
- Drug
- Lead sponsor
- CytoDyn, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Coronado, California • Maitland, Florida • Miami Lakes, Florida + 4 more